152 related articles for article (PubMed ID: 23218026)
41. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
[TBL] [Abstract][Full Text] [Related]
42. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
Rakshit S; Bagchi J; Mandal L; Paul K; Ganguly D; Bhattacharjee S; Ghosh M; Biswas N; Chaudhuri U; Bandyopadhyay S
Apoptosis; 2009 Mar; 14(3):298-308. PubMed ID: 19153832
[TBL] [Abstract][Full Text] [Related]
43. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
[TBL] [Abstract][Full Text] [Related]
44. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.
Kurosu T; Wu N; Oshikawa G; Kagechika H; Miura O
Apoptosis; 2010 May; 15(5):608-20. PubMed ID: 20094798
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways.
Li J; Chen Y; Chen B; Chen C; Qiu B; Zheng Z; Zheng J; Liu T; Wang W; Hu J
J Cancer Res Clin Oncol; 2015 Feb; 141(2):283-93. PubMed ID: 25217883
[TBL] [Abstract][Full Text] [Related]
46. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.
Wang Y; Cai D; Brendel C; Barett C; Erben P; Manley PW; Hochhaus A; Neubauer A; Burchert A
Blood; 2007 Mar; 109(5):2147-55. PubMed ID: 17090651
[TBL] [Abstract][Full Text] [Related]
47. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM
Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
49. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
50. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
51. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.
Sun H; Kapuria V; Peterson LF; Fang D; Bornmann WG; Bartholomeusz G; Talpaz M; Donato NJ
Blood; 2011 Mar; 117(11):3151-62. PubMed ID: 21248063
[TBL] [Abstract][Full Text] [Related]
52. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
Gu JJ; Santiago L; Mitchell BS
Blood; 2005 Apr; 105(8):3270-7. PubMed ID: 15604220
[TBL] [Abstract][Full Text] [Related]
53. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
54. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
[TBL] [Abstract][Full Text] [Related]
55. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Aichberger KJ; Mayerhofer M; Krauth MT; Vales A; Kondo R; Derdak S; Pickl WF; Selzer E; Deininger M; Druker BJ; Sillaber C; Esterbauer H; Valent P
Cancer Res; 2005 Oct; 65(20):9436-44. PubMed ID: 16230407
[TBL] [Abstract][Full Text] [Related]
56. α-bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with Imatinib and Nilotinib.
Bonifacio M; Rigo A; Guardalben E; Bergamini C; Cavalieri E; Fato R; Pizzolo G; Suzuki H; Vinante F
PLoS One; 2012; 7(10):e46674. PubMed ID: 23056396
[TBL] [Abstract][Full Text] [Related]
57. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
[TBL] [Abstract][Full Text] [Related]
58. A common phosphotyrosine signature for the Bcr-Abl kinase.
Goss VL; Lee KA; Moritz A; Nardone J; Spek EJ; MacNeill J; Rush J; Comb MJ; Polakiewicz RD
Blood; 2006 Jun; 107(12):4888-97. PubMed ID: 16497976
[TBL] [Abstract][Full Text] [Related]
59. The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
Deadman BJ; Hopkin MD; Baxendale IR; Ley SV
Org Biomol Chem; 2013 Mar; 11(11):1766-800. PubMed ID: 23247657
[TBL] [Abstract][Full Text] [Related]
60. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.
Bewry NN; Nair RR; Emmons MF; Boulware D; Pinilla-Ibarz J; Hazlehurst LA
Mol Cancer Ther; 2008 Oct; 7(10):3169-75. PubMed ID: 18852120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
